supp.fit
All study protocols

Nicotinamide Riboside: study protocols

7 study groups say how much Nicotinamide Riboside participants took a day. These are the doses the studies gave. They are not a recommendation.

Nicotinamide Riboside: what the research found →

Dose per serving from products

205 products in our catalogue print how much Nicotinamide Riboside a serving holds.

Most common: 250 mg to 500 mg, 51% of 205 products.

Dose per servingProducts
50 mg or less
9
50 mg to 100 mg
19
100 mg to 250 mg
24
250 mg to 500 mg
104
500 mg to 1 g
35
1 g to 2.5 g
14

Dose per serving from research

7 study groups in 4 studies say how much Nicotinamide Riboside participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 500 mg to 1 g, 43% of 7 study groups.

Daily doseStudy groups
100 mg or less
1
100 mg to 250 mg
0
250 mg to 500 mg
1
500 mg to 1 g
3
1 g to 2.5 g
2

Commonly used together

2 of 7 study groups took Nicotinamide Riboside with something else, but nothing that 3 or more different studies gave.

7 study groups

Study
Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19
2021 · CMA group, phase 3 · Adults aged 18–66 with PCR-confirmed mild-to-moderate COVID-19 who did not require hospitalization
2 g2 weeks229
Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19
2021 · CMA group, phase 2 · Adults aged 19–66 with PCR-confirmed mild-to-moderate COVID-19 who did not require hospitalization
2 g2 weeks71
Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy middle-aged and older adults
2018 · NR (nicotinamide riboside) condition · Healthy men and postmenopausal women aged 55–79 years
1 g6 weeks30
The differential impact of three different NAD(+) boosters on circulatory NAD and microbial metabolism in humans
2026 · NR · Healthy adults aged 18–50 years, male and female
1 g2 weeks17
Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults
2019 · 100 mg NIAGEN · Men and non-pregnant, non-breastfeeding women aged 40–60 with BMI 25–30 who were otherwise healthy and overweight
100 mg8 weeks35
Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults
2019 · 300 mg NIAGEN · Men and non-pregnant, non-breastfeeding women aged 40–60 with BMI 25–30 who were otherwise healthy and overweight
300 mg8 weeks35
Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults
2019 · 1000 mg NIAGEN · Men and non-pregnant, non-breastfeeding women aged 40–60 with BMI 25–30 who were otherwise healthy and overweight
1 g8 weeks35